RetinalGeniX Technologies, Inc. operates as a medical device company. The company is headquartered in Petaluma, California and currently employs 0 full-time employees. The company went IPO on 2022-01-07. The firm's proprietary High-Resolution Retinal Imaging and DNA/RNA/GPS Pharmaco-Genetic Mapping technologies are designed to help prevent blindness by detecting initial physiological changes that could indicate future ocular and systemic diseases affecting neurodegenerative, cardiovascular, vascular and metabolic systems, as well as diabetic conditions, Alzheimer’s disease and Parkinson’s disease. Its RetinalCam is an in-home/remote location patient-activated monitoring and imaging device offering real-time communication and alerting system for physicians available 24/7. The company is also engaged in the development of its product candidates: RTG-2023 and RTG-2024. RTG-2023 for the treatment of dry age-related macular degeneration (dry AMD). RTG-2024 for the treatment of Alzheimer’s syndrome dementia.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenue
0
0
0
0
0
0
Revenue Growth (YoY)
--
--
--
--
--
--
Cost of Revenue
--
--
--
--
--
--
Gross Profit
--
--
--
--
--
--
Selling, General & Admin
2
3
1
1
1
1
Research & Development
0
0
0
0
0
0
Operating Expenses
2
4
2
1
2
2
Other Non Operating Income (Expenses)
--
--
--
--
--
--
Pretax Income
-2
-4
-2
-3
-2
-2
Income Tax Expense
--
--
--
--
--
--
Net Income
-2
-4
-2
-3
-2
-2
Net Income Growth
-50%
100%
-33%
50%
0%
--
Shares Outstanding (Diluted)
18.32
17.94
17.35
17.27
14.28
14.28
Shares Change (YoY)
3%
3%
0%
21%
0%
--
EPS (Diluted)
-0.15
-0.24
-0.12
-0.22
-0.15
-0.14
EPS Growth
-34%
100%
-47%
48%
5%
--
Free Cash Flow
0
0
0
0
-1
-1
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
--
--
--
--
--
--
Operating Margin
0%
0%
0%
0%
0%
0%
Profit Margin
0%
0%
0%
0%
0%
0%
Free Cash Flow Margin
0%
0%
0%
0%
0%
0%
EBITDA
-2
-4
-2
-1
--
--
EBITDA Margin
0%
0%
0%
0%
--
--
D&A For EBITDA
0
0
0
0
--
--
EBIT
-2
-4
-2
-1
-2
-2
EBIT Margin
0%
0%
0%
0%
0%
0%
Effective Tax Rate
--
--
--
--
--
--
Follow-Up Questions
What are RetinalGenix Technologies Inc's key financial statements?
According to the latest financial statement (Form-10K), RetinalGenix Technologies Inc has a total asset of $0, Net loss of $-4
What are the key financial ratios for RTGN?
RetinalGenix Technologies Inc's Current ratio is 0, has a Net margin is 0, sales per share of $0.
How is RetinalGenix Technologies Inc's revenue broken down by segment or geography?
RetinalGenix Technologies Inc largest revenue segment is Software, at a revenue of 1,936,990 in the most earnings release.For geography, Canada is the primary market for RetinalGenix Technologies Inc, at a revenue of 1,936,990.
Is RetinalGenix Technologies Inc profitable?
no, according to the latest financial statements, RetinalGenix Technologies Inc has a net loss of $-4
Does RetinalGenix Technologies Inc have any liabilities?
yes, RetinalGenix Technologies Inc has liability of 1
How many outstanding shares for RetinalGenix Technologies Inc?
RetinalGenix Technologies Inc has a total outstanding shares of 18.52